Letters in Drug Design & Discovery

G. Perry
University of Texas
San Antonio, TX
Email: lddd@benthamscience.org


Computational Studies of 1-Hydrazinophthalazine (Hydralazine) as Antineoplasic Agent. Docking Studies on Methyltransferase

Author(s): Enrique Angeles, Victor HugoVazquez-Valadez, Oscar Vazquez-Valadez, Ana Maria Velazquez-Sanchez, Alberto Ramirez, Luisa Martinez, Sandra Diaz-Barriga, Andres Romero-Rojas, Gustavo Cabrera, Rafael Lopez-Castanares, Alfonso Duenas-Gonzalez.


Hydralazine is a drug used as anti-hypertensive, and recently reported to be a DNA methylation inhibitor able to demethylate and reactivate the expression of tumor suppressor genes in cancer. The aim of the present study was to explore the potential mechanism by which hydralazine inhibits DNA methylation. For this purpose, we assessed the structural and electronic properties between 1-hydrazinophthalazine (hydralazine) and a putative ligand methyltransferase.

Keywords: docking, hydralazine, dna methyltransferase, dna methylation inhibitor, tumor suppressor gene

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2005
Page: [282 - 286]
Pages: 5
DOI: 10.2174/1570180054038413
Price: $58